Long-term and late effects of germ cell testicular cancer treatment and implications for follow-up

Journal of Clinical Oncology

Volumn 30, Issue 30, 2012, Pages 3752-3763

  Haugnes, Hege S ^a   Bosl, George J ^e   Boer, Hink ^f   Gietema, Jourik A ^f   Brydyø, Marianne ^b   Oldenburg, Jan ^c   Dahl, Alv A ^c,d   Bremnes, Roy M ^a   Fosså, Sophie D ^c,d  

^a UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF OSLO   (Norway)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN;

AVASCULAR NECROSIS; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; COGNITION; EMPLOYMENT; FATIGUE; FERTILITY; FOLLOW UP; GENETIC SUSCEPTIBILITY; GERM CELL TUMOR; HUMAN; HYPOGONADISM; LIFESTYLE; MALE; MEDICAL ASSESSMENT; MENTAL HEALTH; METASTASIS; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; OTOTOXICITY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; QUALITY OF LIFE; RAYNAUD PHENOMENON; REVIEW; SEXUALITY; TESTIS CANCER; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CARDIOVASCULAR DISEASES; HUMANS; LIFE STYLE; MALE; NEOPLASMS, GERM CELL AND EMBRYONAL; NEOPLASMS, SECOND PRIMARY; RADIOTHERAPY; SURVIVORS; TESTICULAR NEOPLASMS;

EID: 84869231872     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.43.4431     Document Type: Review

References (152)

1. Verdecchia A, Francisci S, Brenner H, et al: Recent cancer survival in Europe: A 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol 8:784-796, 2007 (Pubitemid 47321601)
2. Feldman DR, Bosl GJ, Sheinfeld J, et al: Medical treatment of advanced testicular cancer. JAMA 299:672-684, 2008 (Pubitemid 351252727)
3. Abouassaly R, Fossa SD, Giwercman A, et al: Sequelae of treatment in long-term survivors of testis cancer. Eur Urol 60:516-526, 2011
4. Aziz NM: Cancer survivorship research: State of knowledge, challenges and opportunities. Acta Oncol 46:417-432, 2007
5. Travis LB, Beard C, Allan JM, et al: Testicular cancer survivorship: Research strategies and recommendations. J Natl Cancer Inst 102:1114-1130, 2010
6. Fosså SD, Chen J, Schonfeld SJ, et al: Risk of contralateral testicular cancer: A population-based study of 29,515 U.S. men. J Natl Cancer Inst 97:1056-1066, 2005 (Pubitemid 41417922)
7. Travis LB, Fosså SD, Schonfeld SJ, et al: Second cancers among 40,576 testicular cancer patients: Focus on long-term survivors. J Natl Cancer Inst 97:1354-1365, 2005 (Pubitemid 41487803)
8. Richiardi L, Scélo G, Boffetta P, et al: Second malignancies among survivors of germ-cell testicular cancer: A pooled analysis between 13 cancer registries. Int J Cancer 120:623-631, 2007 (Pubitemid 44969034)
9. van den Belt-Dusebout AW, de Wit R, Gietema JA, et al: Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 25:4370-4378, 2007
10. Howard R, Gilbert E, Lynch CF, et al: Risk of leukemia among survivors of testicular cancer: A population-based study of 42,722 patients. Ann Epidemiol 18:416-421, 2008 (Pubitemid 351728082)
11. Kollmannsberger C, Beyer J, Droz JP, et al: Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors. J Clin Oncol 16:3386-3391, 1998 (Pubitemid 28481637)
12. Houck W, Abonour R, Vance G, et al: Secondary leukemias in refractory germ cell tumor patients undergoing autologous stem-cell transplantation using high-dose etoposide. J Clin Oncol 22:2155-2158, 2004 (Pubitemid 41095149)
13. Wierecky J, Kollmannsberger C, Boehlke I, et al: Secondary leukemia after first-line high-dose chemotherapy for patients with advanced germ cell cancer. J Cancer Res Clin Oncol 131:255-260, 2005 (Pubitemid 40238942)
14. Travis LB, Andersson M, Gospodarowicz M, et al: Treatment-associated leukemia following testicular cancer. J Natl Cancer Inst 92:1165-1171, 2000
15. Fosså SD, Aass N, Kaalhus O: Radiotherapy for testicular seminoma stage I: Treatment results and long-term post-irradiation morbidity in 365 patients. Int J Radiat Oncol Biol Phys 16:383-388, 1989 (Pubitemid 19077203)
16. Tarin TV, Sonn G, Shinghal R: Estimating the risk of cancer associated with imaging related radiation during surveillance for stage I testicular cancer using computerized tomography. J Urol 181:627-632, 2009; discussion 632-633
17. Hall EJ, Brenner DJ: Cancer risks from diagnostic radiology. Br J Radiol 81:362-378, 2008 (Pubitemid 351743850)
18. van Walraven C, Fergusson D, Earle C, et al: Association of diagnostic radiation exposure and second abdominal-pelvic malignancies after testicular cancer. J Clin Oncol 29:2883-2888, 2011
19. Doll DC, List AF, Greco FA, et al: Acute vascular ischemic events after cisplatin-based combination chemotherapy for germ-cell tumors of the testis. Ann Intern Med 105:48-51, 1986 (Pubitemid 16097921)
20. Meinardi MT, Gietema JA, van der Graaf WT, et al: Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol 18:1725-1732, 2000 (Pubitemid 30220551)
21. Zagars GK, Ballo MT, Lee AK, et al: Mortality after cure of testicular seminoma. J Clin Oncol 22:640-647, 2004 (Pubitemid 41095067)
22. Fosså SD, Gilbert E, Dores GM, et al: Non-cancer causes of death in survivors of testicular cancer. J Natl Cancer Inst 99:533-544, 2007 (Pubitemid 47073556)
23. Huddart RA, Norman A, Shahidi M, et al: Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol 21:1513-1523, 2003 (Pubitemid 46594104)
24. van den Belt-Dusebout AW, Nuver J, de Wit R, et al: Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 24:467-475, 2006
25. Haugnes HS, Wethal T, Aass N, et al: Cardiovascular risk factors and morbidity in testicular cancer survivors: A 20 year follow-up study. J Clin Oncol 28:4649-4657, 2010
26. Yusuf S, Hawken S, Ounpuu S, et al: Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet 364:937-952, 2004 (Pubitemid 39208455)
27. Sagstuen H, Aass N, Fosså SD, et al: Blood pressure and body mass index in long-term survivors of testicular cancer. J Clin Oncol 23:4980-4990, 2005 (Pubitemid 46224004)
28. Alberti KG, Zimmet P, Shaw J: The metabolic syndrome: A new worldwide definition. Lancet 366:1059-1062, 2005 (Pubitemid 41338752)
29. Haugnes HS, Aass N, Fosså SD, et al: Components of the metabolic syndrome in long-term survivors of testicular cancer. Ann Oncol 18:241-248, 2007 (Pubitemid 46323088)
30. Nuver J, Smit AJ, Wolffenbuttel BH, et al: The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer. J Clin Oncol 23:3718-3725, 2005
31. Libby P, Ridker PM, Hansson GK: Inflammation in atherosclerosis: From pathophysiology to practice. J Am Coll Cardiol 54:2129-2138, 2009
32. Nuver J, Smit AJ, Sleijfer DT, et al: Microalbuminuria, decreased fibrinolysis, and inflammation as early signs of atherosclerosis in long-term survivors of disseminated testicular cancer. Eur J Cancer 40:701-706, 2004 (Pubitemid 38326620)
33. Sprauten M, Darrah TH, Peterson DR, et al: Impact of long-term platinum concentrations on neuro- and ototoxicity in cisplatin-treated testicular cancer survivors. J Clin Oncol 30:300-307, 2012
34. Gietema JA, Meinardi MT, Messerschmidt J, et al: Circulating plasma platinum more than 10 years after cisplatin treatment for testicular cancer. Lancet 355:1075-1076, 2000 (Pubitemid 30162815)
35. Wethal T, Haugnes HS, Kjekshus J, et al: C-reactive protein: A potential marker of second cancer and cardiovascular disease in testicular cancer survivors? Eur J Cancer 46:3425-3433, 2010
36. Berger CC, Bokemeyer C, Schneider M, et al: Secondary Raynaud's phenomenon and other late vascular complications following chemotherapy for testicular cancer. Eur J Cancer 31A:2229-2238, 1995 (Pubitemid 26050564)
37. Brydøy M, Oldenburg J, Klepp O, et al: Observational study of prevalence of long-term Raynaud-like phenomena and neurological side effects in testicular cancer survivors. J Natl Cancer Inst 101:1682-1695, 2009
38. Rossen PB, Pedersen AF, Zachariae R, et al: Health-Related Quality of Life in Long-Term Survivors of Testicular Cancer. J Clin Oncol 27:5993-5999, 2009
39. Glendenning JL, Barbachano Y, Norman AR, et al: Long-term neurologic and peripheral vascular toxicity after chemotherapy treatment of testicular cancer. Cancer 116:2322-2331, 2010
40. Hansen SW, Olsen N, Rossing N, et al: Vascular toxicity and the mechanism underlying Raynaud's phenomenon in patients treated with cisplatin, vinblastine and bleomycin. Ann Oncol 1:289-292, 1990 (Pubitemid 20377099)
41. Block JA, Sequeira W: Raynaud's phenomenon. Lancet 357:2042-2048, 2001 (Pubitemid 32592397)
42. Carter SK, Blum RH: New chemotherapeutic agents: Bleomycin and adriamycin. CA Cancer J Clin 24:322-331, 1974
43. Comis RL, Kuppinger MS, Ginsberg SJ, et al: Role of single-breath carbon monoxide-diffusing capacity in monitoring the pulmonary effects of bleomycin in germ cell tumor patients. Cancer Res 39:5076-5080, 1979 (Pubitemid 10163118)
44. O'Sullivan JM, Huddart RA, Norman AR, et al: Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann Oncol 14:91-96, 2003 (Pubitemid 36150265)
45. Van Barneveld PW, van der Mark TW, Sleijfer DT, et al: Predictive factors for bleomycin-induced pneumonitis. Am Rev Respir Dis 130:1078-1081, 1984 (Pubitemid 15186168)
46. Dearnaley DP, Horwich A, A'Hern R, et al: Combination chemotherapy with bleomycin, etoposide and cisplatin (BEP) for metastatic testicular teratoma: Long-term follow-up. Eur J Cancer 27:684-691, 1991
47. Nuver J, Lutke Holzik MF, van Zweeden M, et al: Genetic variation in the bleomycin hydrolase gene and bleomycin-induced pulmonary toxicity in germ cell cancer patients. Pharmacogenet Genomics 15:399-405, 2005 (Pubitemid 40835081)
48. Simpson AB, Paul J, Graham J, et al: Fatal bleomycin pulmonary toxicity in the west of Scotland 1991-95: a review of patients with germ cell tumours. Br J Cancer 78:1061-1066, 1998 (Pubitemid 28463983)
49. Van Barneveld PW, Sleijfer DT, van der Mark TW, et al: Natural course of bleomycin-induced pneumonitis: A follow-up study. Am Rev Respir Dis 135:48-51, 1987 (Pubitemid 17223887)
50. Lucraft HH, Wilkinson PM, Stretton TB, et al: Role of pulmonary function tests in the prevention of bleomycin pulmonary toxicity during chemotherapy for metastatic testicular teratoma. Eur J Cancer Clin Oncol 18:133-139, 1982 (Pubitemid 12131133)
51. Osanto S, Bukman A, Van Hoek F, et al: Long-term effects of chemotherapy in patients with testicular cancer. J Clin Oncol 10:574-579, 1992
52. Hansen SW, Groth S, Sørensen PG, et al: Enhanced pulmonary toxicity in smokers with germ-cell cancer treated with cis-platinum, vinblastine and bleomycin: A long-term follow-up. Eur J Cancer Clin Oncol 25:733-736, 1989 (Pubitemid 19096444)
53. Haugnes HS, Aass N, Fosså SD, et al: Pulmonary Function in Long-Term Survivors of Testicular Cancer. J Clin Oncol 27:2779-2786, 2009
54. Mannino DM, Buist AS, Petty TL, et al: Lung function and mortality in the United States: Data from the First National Health and Nutrition Examination Survey follow up study. Thorax 58:388-393, 2003 (Pubitemid 36560940)
55. Schünemann HJ, Dorn J, Grant BJ, et al: Pulmonary function is a long-term predictor of mortality in the general population: 29-year follow-up of the Buffalo Health Study. Chest 118:656-664, 2000
56. Nuver J, De Haas EC, Van Zweeden M, et al: Vascular damage in testicular cancer patients: A study on endothelial activation by bleomycin and cisplatin in vitro. Oncol Rep 23:247-253, 2010
57. Hansen SW, Groth S, Daugaard G, et al: Long-term effects on renal function and blood pressure of treatment with cisplatin, vinblastine, and bleomycin in patients with germ cell cancer. J Clin Oncol 6:1728-1731, 1988 (Pubitemid 19089052)
58. Fosså SD, Aass N, Winderen M, et al: Long-term renal function after treatment for malignant germ-cell tumours. Ann Oncol 13:222-228, 2002 (Pubitemid 34704973)
59. Vickers AE, Rose K, Fisher R, et al: Kidney slices of human and rat to characterize cisplatin-induced injury on cellular pathways and morphology. Toxicol Pathol 32:577-590, 2004 (Pubitemid 39258463)
60. Tanaka H, Ishikawa E, Teshima S, et al: Histopathological study of human cisplatin nephropathy. Toxicol Pathol 14:247-257, 1986 (Pubitemid 16016992)
61. Hodgkinson E, Neville-Webbe HL, Coleman RE: Magnesium depletion in patients receiving cisplatin-based chemotherapy. Clin Oncol (R Coll Radiol) 18:710-718, 2006 (Pubitemid 44464042)
62. Willox JC, McAllister EJ, Sangster G, et al: Effects of magnesium supplementation in testicular cancer patients receiving cis-platin: A randomised trial. Br J Cancer 54:19-23, 1986 (Pubitemid 16093180)
63. Dentino M, Luft FC, Yum MN, et al: Long term effect of cis-diamminedichloride platinum (CDDP) on renal function and structure in man. Cancer 41:1274-1281, 1978 (Pubitemid 8350173)
64. Schilsky RL, Anderson T: Hypomagnesemia and renal magnesium wasting in patients receiving cisplatin. Ann Intern Med 90:929-931, 1979 (Pubitemid 9244593)
65. Vogelzang NJ, Torkelson JL, Kennedy BJ: Hypomagnesemia, renal dysfunction, and Raynaud's phenomenon in patients treated with cisplatin, vinblastine, and bleomycin. Cancer 56:2765-2770, 1985 (Pubitemid 16216283)
66. Schilsky RL, Barlock A, Ozols RF: Persistent hypomagnesemia following cisplatin chemotherapy for testicular cancer. Cancer Treat Rep 66:1767-1769, 1982 (Pubitemid 12000635)
67. Hamdi T, Latta S, Jallad B, et al: Cisplatin-induced renal salt wasting syndrome. South Med J 103:793-799, 2010
68. Daugaard G, Abildgaard U: Cisplatin nephrotoxicity: A review. Cancer Chemother Pharmacol 25:1-9, 1989
69. Daugaard G, Rossing N, Rørth M: Effects of cisplatin on different measures of glomerular function in the human kidney with special emphasis on high-dose. Cancer Chemother Pharmacol 21:163-167, 1988 (Pubitemid 18087031)
70. Hartmann JT, Kollmannsberger C, Kanz L, et al: Platinum organ toxicity and possible prevention in patients with testicular cancer. Int J Cancer 83:866-869, 1999
71. Bosl GJ, Leitner SP, Atlas SA, et al: Increased plasma renin and aldosterone in patients treated with cisplatin-based chemotherapy for metastatic germ-cell tumors. J Clin Oncol 4:1684-1689, 1986 (Pubitemid 17188938)
72. Meijer S, Mulder NH, Sleijfer DT, et al: Nephrotoxicity of cis-diamminedichloride platinum (CDDP) during remission-induction and maintenance chemotherapy of testicular carcinoma. Cancer Chemother Pharmacol 8:27-30, 1982 (Pubitemid 12161609)
73. Bali L, Silhol F, Kateb A, et al: Renal artery stenosis after abdominal radiotherapy [in French]. Ann Cardiol Angeiol (Paris) 58:183-186, 2009
74. Mulla MG, Ananthkrishnan G, Mirza MS, et al: Renal artery stenosis after radiotherapy for stage I seminoma, a case report. Clin Oncol (R Coll Radiol) 19:209, 2007
75. Peacock JM, Ohira T, Post W, et al: Serum magnesium and risk of sudden cardiac death in the Atherosclerosis Risk in Communities (ARIC) study. Am Heart J 160:464-470, 2010
76. Astor BC, Hallan SI, Miller ER 3rd, et al: Glomerular filtration rate, albuminuria, and risk of cardiovascular and all-cause mortality in the US population. Am J Epidemiol 167:1226-1234, 2008 (Pubitemid 351670638)
77. Gansevoort RT, Matsushita K, van der Velde M, et al: Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes in both general and high-risk populations: A collaborative meta-analysis of general and high-risk population cohorts. Kidney Int 80:93-104, 2011
78. Krarup-Hansen A, Helweg-Larsen S, Schmalbruch H, et al: Neuronal involvement in cisplatin neuropathy: Prospective clinical and neurophysiological studies. Brain 130:1076-1088, 2007 (Pubitemid 47355585)
79. Hausheer FH, Schilsky RL, Bain S, et al: Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol 33:15-49, 2006 (Pubitemid 43214485)
80. Kollmannsberger C, Kuzcyk M, Mayer F, et al: Late toxicity following curative treatment of testicular cancer. Semin Surg Oncol 17:275-281, 1999
81. Wolf S, Barton D, Kottschade L, et al: Chemotherapy-induced peripheral neuropathy: Prevention and treatment strategies. Eur J Cancer 44:1507-1515, 2008
82. Bauer CA, Brozoski TJ: Cochlear structure and function after round window application of ototoxins. Hear Res 201:121-131, 2005 (Pubitemid 40255551)
83. Bokemeyer C, Berger CC, Hartmann JT, et al: Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. Br J Cancer 77:1355-1362, 1998 (Pubitemid 28140629)
84. Bokemeyer C, Berger CC, Kuczyk MA, et al: Evaluation of long-term toxicity after chemotherapy for testicular cancer. J Clin Oncol 14:2923-2932, 1996 (Pubitemid 26371450)
85. Fosså SD, de Wit R, Roberts JT, et al: Quality of life in good prognosis patients with metastatic germ cell cancer: A prospective study of the European Organisation for Research and Treatment of Cancer Genitourinary Group/Medical Research Council Testicular Cancer Study Group (30941/TE20). J Clin Oncol 21:1107-1118, 2003 (Pubitemid 46594141)
86. Oldenburg J, Kraggerud SM, Cvancarova M, et al: Cisplatin-induced long-term hearing impairment is associated with specific glutathione s-transferase genotypes in testicular cancer survivors. J Clin Oncol 25:708-714, 2007 (Pubitemid 350002927)
87. Oldenburg J, Kraggerud SM, Brydøy M, et al: Association between long-term neuro-toxicities in testicular cancer survivors and polymorphisms in glutathione-s-transferase-P1 and -M1, a retrospective cross sectional study. J Transl Med 5:70, 2007
88. Ross CJ, Katzov-Eckert H, Dubé MP, et al: Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nat Genet 41:1345-1349, 2009
89. Riedemann L, Lanvers C, Deuster D, et al: Megalin genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Pharmacogenomics J 8:23-28, 2008
90. Skoogh J, Steineck G, Stierner U, et al: Testicular-cancer survivors experience compromised language following chemotherapy: Findings in a Swedish population-based study 3-26 years after treatment. Acta Oncol 51:185-197, 2012
91. Pedersen AD, Rossen P, Mehlsen MY, et al: Long-term cognitive function following chemotherapy in patients with testicular cancer. J Int Neuropsychol Soc 15:296-301, 2009
92. Schagen SB, Boogerd W, Muller MJ, et al: Cognitive complaints and cognitive impairment following BEP chemotherapy in patients with testicular cancer. Acta Oncol 47:63-70, 2008
93. Skaali T, Fosså SD, Andersson S, et al: Self-reported cognitive problems in testicular cancer patients: Relation to neuropsychological performance, fatigue, and psychological distress. J Psychosom Res 70:403-410, 2011
94. Shim K, MacKenzie MJ, Winquist E: Chemotherapy-associated osteonecrosis in cancer patients with solid tumours: A systematic review. Drug Saf 31:359-371, 2008 (Pubitemid 351565736)
95. Winquist EW, Bauman GS, Balogh J: Non-traumatic osteonecrosis after chemotherapy for testicular cancer: A systematic review. Am J Clin Oncol 24:603-606, 2001 (Pubitemid 33131424)
96. Cook AM, Dzik-Jurasz AS, Padhani AR, et al: The prevalence of avascular necrosis in patients treated with chemotherapy for testicular tumours. Br J Cancer 85:1624-1626, 2001 (Pubitemid 34081503)
97. Gerl A, Mühlbayer D, Hansmann G, et al: The impact of chemotherapy on Leydig cell function in long term survivors of germ cell tumors. Cancer 91:1297-1303, 2001 (Pubitemid 32267041)
98. Wiechno P, Demkow T, Kubiak K, et al: The quality of life and hormonal disturbances in testicular cancer survivors in cisplatin era. Eur Urol 52:1448-1454, 2007
99. Huddart RA, Norman A, Moynihan C, et al: Fertility, gonadal and sexual function in survivors of testicular cancer. Br J Cancer 93:200-207, 2005 (Pubitemid 41133206)
100. Palmieri G, Lotrecchiano G, Ricci G, et al: Gonadal function after multimodality treatment in men with testicular germ cell cancer. Eur J Endocrinol 134:431-436, 1996 (Pubitemid 26155504)
101. Hansen SW, Berthelsen JG, von der Maase H: Long-term fertility and Leydig cell function in patients treated for germ cell cancer with cisplatin, vinblastine, and bleomycin versus surveillance. J Clin Oncol 8:1695-1698, 1990 (Pubitemid 20334324)
102. Nord C, Bjøro T, Ellingsen D, et al: Gonadal hormones in long-term survivors 10 years after treatment for unilateral testicular cancer. Eur Urol 44:322-328, 2003 (Pubitemid 37051700)
103. Brand JS, van der Tweel I, Grobbee DE, et al: Testosterone, sex hormone-binding globulin and the metabolic syndrome: A systematic review and meta-analysis of observational studies. Int J Epidemiol 40:189-207, 2011
104. Araujo AB, Kupelian V, Page ST, et al: Sex steroids and all-cause and cause-specific mortality in men. Arch Intern Med 167:1252-1260, 2007 (Pubitemid 46998496)
105. Laughlin GA, Barrett-Connor E, Bergstrom J: Low serum testosterone and mortality in older men. J Clin Endocrinol Metab 93:68-75, 2008
106. Brown JE, Ellis SP, Silcocks P, et al: Effect of chemotherapy on skeletal health in male survivors from testicular cancer and lymphoma. Clin Cancer Res 12:6480-6486, 2006 (Pubitemid 44799721)
107. Ondrusova M, Ondrus D, Dusek L, et al: Damage of hormonal function and bone metabolism in long-term survivors of testicular cancer. Neoplasma 56:473-479, 2009
108. Bhasin S, Cunningham GR, Hayes FJ, et al: Testosterone therapy in men with androgen deficiency syndromes: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 95:2536-2559, 2010
109. Huyghe E, Matsuda T, Daudin M, et al: Fertility after testicular cancer treatments: Results of a large multicenter study. Cancer 100:732-737, 2004 (Pubitemid 38176850)
110. Brydøy M, Fosså SD, Klepp O, et al: Paternity following treatment for testicular cancer. J Natl Cancer Inst 97:1580-1588, 2005 (Pubitemid 41662712)
111. Matos E, Skrbinc B, Zakotnik B: Fertility in patients treated for testicular cancer. J Cancer Surviv 4:274-278, 2010
112. Spermon JR, Kiemeney LA, Meuleman EJ, et al: Fertility in men with testicular germ cell tumors. Fertil Steril 79:1543-1549, 2003 (suppl 3)
113. Brydøy M, Fosså SD, Klepp O, et al: Paternity and testicular function among testicular cancer survivors treated with two to four cycles of cisplatin-based chemotherapy. Eur Urol 58:134-141, 2010
114. Beck SD, Bey AL, Bihrle R, et al: Ejaculatory status and fertility rates after primary retroperitoneal lymph node dissection. J Urol 184:2078-2080, 2010
115. Heidenreich A, Albers P, Hartmann M, et al: Complications of primary nerve sparing retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumors of the testis: Experience of the German Testicular Cancer Study Group. J Urol 169:1710-1714, 2003 (Pubitemid 36443478)
116. Subramanian VS, Nguyen CT, Stephenson AJ, et al: Complications of open primary and postchemotherapy retroperitoneal lymph node dissection for testicular cancer. Urol Oncol 28:504-509, 2010
117. Jacobsen KD, Ous S, Waehre H, et al: Ejaculation in testicular cancer patients after post-chemotherapy retroperitoneal lymph node dissection. Br J Cancer 80:249-255, 1999 (Pubitemid 29210114)
118. Pettus JA, Carver BS, Masterson T, et al: Preservation of ejaculation in patients undergoing nerve-sparing postchemotherapy retroperitoneal lymph node dissection for metastatic testicular cancer. Urology 73:328-331, 2009
119. Coogan CL, Hejase MJ, Wahle GR, et al: Nerve sparing post-chemotherapy retroperitoneal lymph node dissection for advanced testicular cancer. J Urol 156:1656-1658, 1996 (Pubitemid 26344013)
120. Heidenreich A, Pfister D, Witthuhn R, et al: Postchemotherapy retroperitoneal lymph node dissection in advanced testicular cancer: Radical or modified template resection. Eur Urol 55:217-224, 2009
121. Lampe H, Horwich A, Norman A, et al: Fertility after chemotherapy for testicular germ cell cancers. J Clin Oncol 15:239-245, 1997 (Pubitemid 27020579)
122. Petersen PM, Hansen SW, Giwercman A, et al: Dose-dependent impairment of testicular function in patients treated with cisplatin-based chemotherapy for germ cell cancer. Ann Oncol 5:355-358, 1994 (Pubitemid 2080191)
123. Gandini L, Sgrò P, Lombardo F, et al: Effect of chemo- or radiotherapy on sperm parameters of testicular cancer patients. Hum Reprod 21:2882-2889, 2006 (Pubitemid 44567002)
124. Reiter WJ, Kratzik C, Brodowicz T, et al: Sperm analysis and serum follicle-stimulating hormone levels before and after adjuvant single-agent carboplatin therapy for clinical stage I seminoma. Urology 52:117-119, 1998 (Pubitemid 28317940)
125. Pectasides D, Pectasides E, Papaxoinis G, et al: Testicular function in poor-risk nonseminomatous germ cell tumors treated with methotrexate, paclitaxel, ifosfamide, and cisplatin combination chemotherapy. J Androl 30:280-286, 2009
126. Ishikawa T, Kamidono S, Fujisawa M: Fertility after high-dose chemotherapy for testicular cancer. Urology 63:137-140, 2004 (Pubitemid 38147567)
127. Nazareth I, Lewin J, King M: Sexual dysfunction after treatment for testicular cancer: A systematic review. J Psychosom Res 51:735-743, 2001 (Pubitemid 34055800)
128. Dahl AA, Bremnes R, Dahl O, et al: Is the sexual function compromised in long-term testicular cancer survivors? Eur Urol 52:1438-1447, 2007 (Pubitemid 47445974)
129. Tuinman MA, Fleer J, Sleijfer DT, et al: Marital and sexual satisfaction in testicular cancer survivors and their spouses. Support Care Cancer 13:540-548, 2005 (Pubitemid 40933612)
130. Orre IJ, Fosså SD, Murison R, et al: Chronic cancer-related fatigue in long-term survivors of testicular cancer. J Psychosom Res 64:363-371, 2008 (Pubitemid 351417918)
131. Orre IJ, Murison R, Dahl AA, et al: Levels of circulating interleukin-1 receptor antagonist and C-reactive protein in long-term survivors of testicular cancer with chronic cancer-related fatigue. Brain Behav Immun 23:868-874, 2009
132. Dahl AA, Haaland CF, Mykletun A, et al: Study of anxiety disorder and depression in long-term survivors of testicular cancer. J Clin Oncol 23:2389-2395, 2005 (Pubitemid 46218733)
133. Shinn EH, Basen-Engquist K, Thornton B, et al: Health behaviors and depressive symptoms in testicular cancer survivors. Urology 69:748-753, 2007 (Pubitemid 46574916)
134. Shinn EH, Swartz RJ, Thornton BB, et al: Testis cancer survivors' health behaviors: Comparison with age-matched relative and demographically matched population controls. J Clin Oncol 28:2274-2279, 2010
135. de Boer AG, Taskila T, Ojajärvi A, et al: Cancer survivors and unemployment: A meta-analysis and meta-regression. JAMA 301:753-762, 2009
136. Berg Gudbergsson S, Fosså SD, Dahl AA: Is cancer survivorship associated with reduced work engagement? A NOCWO study. J Cancer Surviv 2:159-168, 2008
137. Fleer J, Hoekstra HJ, Sleijfer DT, et al: Quality of life of testicular cancer survivors and the relationship with sociodemographics, cancer-related variables, and life events. Support Care Cancer 14:251-259, 2006 (Pubitemid 43247929)
138. Mykletun A, Dahl AA, Haaland CF, et al: Side effects and cancer-related stress determine quality of life in long-term survivors of testicular cancer. J Clin Oncol 23:3061-3068, 2005 (Pubitemid 46224128)
139. Dahl AA, Mykletun A, Fosså SD: Quality of life in survivors of testicular cancer. Urol Oncol 23:193-200, 2005 (Pubitemid 40720386)
140. Schwartz CE, Andresen EM, Nosek MA, et al: Response shift theory: Important implications for measuring quality of life in people with disability. Arch Phys Med Rehabil 88:529-536, 2007 (Pubitemid 46482431)
141. Day RW: Future need for more cancer research. J Am Diet Assoc 98:523, 1998
142. Demark-Wahnefried W, Aziz NM, Rowland JH, et al: Riding the crest of the teachable moment: Promoting long-term health after the diagnosis of cancer. J Clin Oncol 23:5814-5830, 2005
143. Schairer C, Hisada M, Chen BE, et al: Comparative mortality for 621 second cancers in 29,356 testicular cancer survivors and 12,420 matched first cancers. J Natl Cancer Inst 99:1248-1256, 2007 (Pubitemid 47299903)
144. Brown BW, Brauner C, Minnotte MC: Non-cancer deaths in white adult cancer patients. J Natl Cancer Inst 85:979-987, 1993 (Pubitemid 23177584)
145. Ganz PA: Late effects of cancer and its treatment. Semin Oncol Nurs 17:241-248, 2001
146. Meadows AT, Varricchio C, Crosson K, et al: Research issues in cancer survivorship: Report of a workshop sponsored by the Office of Cancer Survivorship, National Cancer Institute. Cancer Epidemiol Biomarkers Prev 7:1145-1151, 1998 (Pubitemid 29001672)
147. Aziz NM, Rowland JH: Trends and advances in cancer survivorship research: Challenge and opportunity. Semin Radiat Oncol 13:248-266, 2003 (Pubitemid 36962648)
148. Bellizzi KM, Rowland JH, Jeffery DD, et al: Health behaviors of cancer survivors: Examining opportunities for cancer control intervention. J Clin Oncol 23:8884-8893, 2005 (Pubitemid 46217465)
149. Demark-Wahnefried W, Jones LW: Promoting a healthy lifestyle among cancer survivors. Hematol Oncol Clin North Am 22:319-342, viii, 2008
150. Irwin ML: Physical activity interventions for cancer survivors. Br J Sports Med 43:32-38, 2009
151. Hentrich M, Fegg MJ, Meiler S, et al: Smoking cessation in long-term survivors of germ cell tumour. J Cancer Res Clin Oncol 132:557-560, 2006 (Pubitemid 44078524)
152. Thorsen L, Skovlund E, Strømme SB, et al: Effectiveness of physical activity on cardiorespiratory fitness and health-related quality of life in young and middle-aged cancer patients shortly after chemotherapy. J Clin Oncol 23:2378-2388, 2005 (Pubitemid 46218732)